PER 2.47% 8.3¢ percheron therapeutics limited

1102 MS partnership

  1. 960 Posts.
    lightbulb Created with Sketch. 322
    From the company update on 9/12/14

    With respect to ATL1102 for MS, the Company recently received a positive response from the US Food and Drug Administration following the agency’s Pre-IND assessment of the development strategy for ATL1102, including plans for a Phase IIb trial in MS patients (ASX: ATL1102 for MS – FDA Response to Phase IIb Study Plans, 24 October 2014). Destum have similarly been engaged to help ANP find a suitable development partner for ATL1102. Both ANP and Destum are in ongoing dialogue with potential pharmaceutical company partners. The process of attracting a suitable partner for ATL1102 is anticipated to take up to six months.

    So does this mean that we are expecting a second parnership deal in the next few weeks? Also....

    ANP is currently investigating provision of ATL1102 under an Early Access Program (EAP) on compassionate use or on a named patient basis in markets where the drug would qualify for use on these grounds including those where the Company can charge for drug access resulting in a possible early income stream. These investigations are moving forward positively with the Company having identified a potential existing source of ATL1102 material for use in an EAP. Assuming all the material will be available and suitable for use (to be confirmed in ongoing technical diligence and business follow up) ANP estimates there would be sufficient quantities for one year’s treatment for approximately 200 patients1 . ANP is in discussions with an experienced European based group to set up and run the program in Europe for ANP. Pricing for such EAP access for patients to use ATL1102 would be determined with the insight of the European firm, however as a point of reference the hospital price of TysabriTM in Europe ranges from A$25-$33,000 per patient per annum2 . ANP expects to update the market on the progress of this use of ATL1102 in the coming months as key components are confirmed. As outlined earlier, ANP’s plans are to conduct a Phase IIb trial of ATL1102 with a funding and development partner. The Company is currently engaged in the process to attract a partner.

    If we get 200 patients x $30,000 per year = $6 million per year.

    OK so my take is that a number of trader who listened to ITSA's projections of $1-2 have jumped the gun assuming that he was referring to 1103 only. (He may have said that, not sure, he is a wealth of research information but he is also a very naughty boy $$$$). So 3 Million shares have been dumped. But if you take into account the above MS potential with 1102 then he may very well be right. We now have cash backing to negotiate with confidence for a deal for 1102 for MS and huge potential revenues from an EAP program. The traders should have paid more attention to KP who was on the money for 1103.....

    My message is get over it.... the company was cash strapped and has to make deal happen fast and they did. We are now in a position of confidence going into the MS partnership deal (which is where the real money is) and 1103 developement is fully funded with royalties at the end. Looking forward to the next few weeks with anticipation. Good luck to all and dont give your shares away at these prices, more to come.... and yes I have also discovered the bold button
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.3¢
Change
0.002(2.47%)
Mkt cap ! $74.82M
Open High Low Value Volume
9.0¢ 9.0¢ 8.2¢ $9.57K 112.6K

Buyers (Bids)

No. Vol. Price($)
2 124862 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 11000 1
View Market Depth
Last trade - 15.56pm 28/03/2024 (20 minute delay) ?
Last
8.2¢
  Change
0.002 ( 0.86 %)
Open High Low Volume
8.2¢ 8.3¢ 8.2¢ 31700
Last updated 15.55pm 28/03/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.